Intermittent Androgen Deprivation: Clinical Experience and Practical Applications

Urologic Clinics of North America

Volumn 33, Issue 2, 2006, Pages 167-179

  Wright, Jonathan L ^a   Higano, Celestia S ^b   Lin, Daniel W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR; FINASTERIDE; FLUTAMIDE; FOSFESTROL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CANADA; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CHRONOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTINUOUS ANDROGEN DEPRIVATION THERAPY; DEPLETION; DISEASE COURSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENERGY; EXPERIENCE; FATIGUE; FEASIBILITY STUDY; GYNECOMASTIA; HORMONAL REGULATION; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; LABORATORY; LANGUAGE DISABILITY; LIBIDO DISORDER; LIFE EXPECTANCY; MALE SEXUAL DYSFUNCTION; MEMORY DISORDER; MONOTHERAPY; NONHUMAN; ONSET AGE; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PORTUGAL; POTENCY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VERBAL MEMORY; WELLBEING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; DIETHYLSTILBESTROL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33646027312     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.12.013     Document Type: Review

References (69)

1. Huggins C., and Hodges C. Studies on prostate cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
3. Higano C.S. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61 (2003) 32-38
4. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171 (2004) 1393-1401
5. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981-989
6. Isaacs J.T., and Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41 (1981) 5070-5075
7. Buchanan G., Greenberg N.M., Scher H.I., et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7 (2001) 1273-1281
8. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
9. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
10. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997) 314-319
11. Raffo A.J., Perlman H., Chen M.W., et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55 (1995) 4438-4445
12. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64 (2004) 6595-6602
13. Nelson P.S., Clegg N., Arnold H., et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99 (2002) 11890-11895
14. Bruchovsky N., Rennie P.S., Coldman A.J., et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50 (1990) 2275-2282
15. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790
16. Bruchovsky N., Snoek R., Rennie P.S., et al. Control of tumor progression by maintenance of apoptosis. Prostate Suppl 6 (1996) 13-21
17. Akakura K., Bruchovsky N., Rennie P.S., et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 59 (1996) 501-511
18. Sato N., Gleave M.E., Bruchovsky N., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58 (1996) 139-146
19. Buhler K.R., Santucci R.A., Royai R.A., et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. Prostate 43 (2000) 63-70
20. Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 137 (1987) 785-788
21. Russo P., Liguori G., Heston W.D., et al. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res 47 (1987) 5967-5970
22. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995) 839-844 [discussion: 844-5]
23. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol-a protocol for reversible medical castration. Urology 47 (1996) 882-884
24. Higano C.S., Ellis W., Russell K., et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 48 (1996) 800-804
25. Oefelein M.G. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 160 (1998) 1685-1688
26. Hall M.C., Fritzsch R.J., Sagalowsky A.I., et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 53 (1999) 898-902 [discussion: 902-3]
27. Nejat R.J., Rashid H.H., Bagiella E., et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
28. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
29. Bouchot O., Lenormand L., Karam G., et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 38 (2000) 543-549
30. Crook J.M., Szumacher E., Malone S., et al. Intermittent androgen suppression in the management of prostate cancer. Urology 53 (1999) 530-534
31. Kurek R., Renneberg H., Lubben G., et al. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 Suppl 1 (1999) 27-31
32. Sato N., Akakura K., Isaka S., et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64 (2004) 341-345
33. Strum S.B., Scholz M.C., and McDermed J.E. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 5 (2000) 45-52
34. Leibowitz R.L., and Tucker S.J. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 6 (2001) 177-182
35. Klotz L.H., Herr H.W., Morse M.J., et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 (1986) 2546-2550
36. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 44 (2003) 505-511
37. Higano C., Shields A., Wood N., et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 (2004) 1182-1186
38. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 (2003) 1808-1811
39. Almeida O.P., Waterreus A., Spry N., et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 29 (2004) 1071-1081
40. Horwich A., Huddart R.A., Gadd J., et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 81 (1998) 96-99
41. Oliver R.T., Williams G., Paris A.M., et al. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49 (1997) 79-82
42. Gleave M., Goldenberg S.L., Bruchovsky N., et al. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis 1 (1998) 289-296
43. Goldenberg S.L., Gleave M.E., Taylor D., et al. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol 3 (1999) 287-292
44. Hurtado-Coll A., Goldenberg S.L., Gleave M.E., et al. Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 60 (2002) 52-56 [discussion 56]
45. Pether M., and Goldenberg S.L. Intermittent androgen suppression. BJU Int 93 (2004) 258-261
46. Pether M., Goldenberg S.L., Bhagirath K., et al. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 10 (2003) 1809-1814
47. Grossfeld G.D., Small E.J., and Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 51 (1998) 137-144
48. Peyromaure M., Delongchamps N.B., Debre B., et al. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 65 (2005) 724-729
49. De La Taille A., Zerbib M., Conquy S., et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 91 (2003) 18-22
50. Prapotnich D., Fizazi K., Escudier B., et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43 (2003) 233-239 [discussion 239-40]
51. Youssef E., Tekyi-Mensah S., Hart K., et al. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer. Am J Clin Oncol 26 (2003) e119-e123
52. de Leval J., Boca P., Yousef E., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1 (2002) 163-171
53. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235-246
54. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
55. Iversen P., Johansson J.E., Lodding P., et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172 (2004) 1871-1876
56. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
57. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
58. Miller J., Ahmann A., Drach G., et al. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147 (1992) 956-961
59. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166 (2001) 500-506 [discussion 506-7]
60. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155 (1996) 213-219
61. July L.V., Akbari M., Zellweger T., et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (2002) 179-188
62. Paterson R.F., Gleave M.E., Jones E.C., et al. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 3 (1999) 277-286
63. Tsuji M., Murakami Y., Kanayama H., et al. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 81 (1998) 116-121
64. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
65. D'Amico A.V., Moul J.W., Carroll P.R., et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 96 (2004) 509-515
66. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
67. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
68. Patel D.A., Presti Jr. J.C., McNeal J.E., et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157-6162
69. Arlen P.M., Figg W.D., Gulley J., et al. National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer 1 (2002) 153-162